factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 396-409 | 402-409 | T35 | obese patient | PROCESS_OF | 396 | 409 | preserve | 396-401 | 396-401 | T31 | obese | DiseaseOrSyndrome | 396 | 401 | preserve | 402-409 | 402-409 | T32 | patient | PatientOrDisabledGroup | 402 | 409 | A7 | This retrospective study was performed to compare the outcome of laparoscopic versus open renal and adrenal surgery in the markedly and morbidly obese patient (body mass index 30 or greater). | 238-448 | 238 | 448 | This retrospective study was performed to compare the outcome of laparoscopic versus open renal and adrenal surgery in the markedly and morbidly @SUBJECT$ @PREDICAT$ @OBJECT$ (body mass index 30 or greater). |
Fact | preserve | 39-41 | 39-41 | T9 | in | TREATS | 39 | 41 | preserve | 31-38 | 31-38 | T4 | surgery | TherapeuticOrPreventiveProcedure | 31 | 38 | preserve | 48-56 | 48-56 | T6 | patients | PatientOrDisabledGroup | 48 | 56 | A9 | Laparoscopic renal and adrenal surgery in obese patients: comparison to open surgery. | 0-91 | 0 | 91 | Laparoscopic renal and adrenal @SUBJECT$ @PREDICAT$ obese @OBJECT$ : comparison to open surgery. |
Fact | preserve | 2221-2229 | 2221-2229 | T145 | compared | compared_with | 2,221 | 2,229 | preserve | 2135-2142 | 2135-2142 | T130 | surgery | TherapeuticOrPreventiveProcedure | 2,135 | 2,142 | preserve | 2235-2247 | 2240-2247 | T134 | open surgery | TherapeuticOrPreventiveProcedure | 2,235 | 2,247 | A10 | Our data suggest that laparoscopic renal and adrenal surgery is technically feasible in the markedly and morbidly obese patient, and compared with open surgery results in significantly decreased blood loss, quicker return of bowel function, less analgesic requirement, shorter convalescence and reduced hospital stay. | 2075-2417 | 2,075 | 2,417 | Our data suggest that laparoscopic renal and adrenal @SUBJECT$ is technically feasible in the markedly and morbidly obese patient, and @PREDICAT$ with @OBJECT$ results in significantly decreased blood loss, quicker return of bowel function, less analgesic requirement, shorter convalescence and reduced hospital stay. |
Fact | preserve | 42-56 | 48-56 | T8 | obese patients | PROCESS_OF | 42 | 56 | preserve | 42-47 | 42-47 | T5 | obese | DiseaseOrSyndrome | 42 | 47 | preserve | 48-56 | 48-56 | T6 | patients | PatientOrDisabledGroup | 48 | 56 | A12 | Laparoscopic renal and adrenal surgery in obese patients: comparison to open surgery. | 0-91 | 0 | 91 | Laparoscopic renal and adrenal surgery in @SUBJECT$ @PREDICAT$ @OBJECT$ : comparison to open surgery. |
Fact | preserve | 1144-1158 | 1150-1158 | T84 | obese patients | PROCESS_OF | 1,144 | 1,158 | preserve | 1144-1149 | 1144-1149 | T78 | obese | DiseaseOrSyndrome | 1,144 | 1,149 | preserve | 1150-1158 | 1150-1158 | T79 | patients | PatientOrDisabledGroup | 1,150 | 1,158 | A14 | RESULTS: There were 21 obese patients in each group and baseline parameters were comparable between groups. | 1121-1234 | 1,121 | 1,234 | RESULTS: There were 21 @SUBJECT$ @PREDICAT$ @OBJECT$ in each group and baseline parameters were comparable between groups. |
Fact | preserve | 207-209 | 207-209 | T21 | in | TREATS | 207 | 209 | preserve | 199-206 | 199-206 | T16 | surgery | TherapeuticOrPreventiveProcedure | 199 | 206 | preserve | 216-224 | 216-224 | T18 | patients | PatientOrDisabledGroup | 216 | 224 | A15 | PURPOSE: The efficacy and morbidity of laparoscopic renal and adrenal surgery in comparison to open surgery in obese patients are unknown. | 92-237 | 92 | 237 | PURPOSE: The efficacy and morbidity of laparoscopic renal and adrenal surgery in comparison to open @SUBJECT$ @PREDICAT$ obese @OBJECT$ are unknown. |
Fact | preserve | 1027-1053 | 1037-1053 | T67 | adenosine echocardiography | USES | 1,027 | 1,053 | preserve | 1037-1053 | 1037-1053 | T61 | echocardiography | DiagnosticProcedure | 1,037 | 1,053 | preserve | 1027-1036 | 1027-1036 | T60 | adenosine | BiologicallyActiveSubstance | 1,027 | 1,036 | A2 | The sensitivity of adenosine echocardiography and thallium scintigraphy were 96% and 88%, respectively, for detecting greater than 75% stenosis. | 1008-1165 | 1,008 | 1,165 | The sensitivity of @OBJECT$ @PREDICAT$ @SUBJECT$ and thallium scintigraphy were 96% and 88%, respectively, for detecting greater than 75% stenosis. |
Probable | preserve | 2349-2355 | 2349-2355 | T150 | detect | DIAGNOSES | 2,349 | 2,355 | preserve | 2328-2344 | 2328-2344 | T138 | echocardiography | DiagnosticProcedure | 2,328 | 2,344 | preserve | 2368-2385 | 2377-2385 | T140 | coronary stenoses | DiseaseOrSyndrome | 2,368 | 2,385 | A3 | Therefore, we conclude that adenosine echocardiography can detect significant coronary stenoses, has a high degree of concordance with thallium in detecting cardiac perfusion abnormalities, and can assess myocardial viability following thrombolytic therapy. | 2284-2559 | 2,284 | 2,559 | Therefore, we conclude that adenosine @SUBJECT$ can @PREDICAT$ significant @OBJECT$ , has a high degree of concordance with thallium in detecting cardiac perfusion abnormalities, and can assess myocardial viability following thrombolytic therapy. |
Fact | preserve | 556-563 | 556-563 | T44 | treated | TREATS | 556 | 563 | preserve | 569-589 | 582-589 | T29 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 569 | 589 | preserve | 502-523 | 513-523 | T27 | myocardial infarction | DiseaseOrSyndrome | 502 | 523 | A4 | Therefore, in 40 patients with either unstable angina, non-Q myocardial infarction, or myocardial infarction treated with thrombolytic therapy, we performed adenosine echocardiography (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. | 435-839 | 435 | 839 | Therefore, in 40 patients with either unstable angina, non-Q @OBJECT$ , or myocardial infarction @PREDICAT$ with @SUBJECT$ , we performed adenosine echocardiography (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. |
Fact | preserve | 594-603 | 594-603 | T46 | performed | ADMINISTERED_TO | 594 | 603 | preserve | 614-630 | 614-630 | T31 | echocardiography | DiagnosticProcedure | 614 | 630 | preserve | 452-460 | 452-460 | T25 | patients | PatientOrDisabledGroup | 452 | 460 | A5 | Therefore, in 40 patients with either unstable angina, non-Q myocardial infarction, or myocardial infarction treated with thrombolytic therapy, we performed adenosine echocardiography (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. | 435-839 | 435 | 839 | Therefore, in 40 @OBJECT$ with either unstable angina, non-Q myocardial infarction, or myocardial infarction treated with thrombolytic therapy, we @PREDICAT$ adenosine @SUBJECT$ (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. |
Fact | preserve | 1846-1872 | 1856-1872 | T119 | adenosine echocardiography | USES | 1,846 | 1,872 | preserve | 1856-1872 | 1856-1872 | T112 | echocardiography | DiagnosticProcedure | 1,856 | 1,872 | preserve | 1846-1855 | 1846-1855 | T111 | adenosine | BiologicallyActiveSubstance | 1,846 | 1,855 | A6 | In 13 patients receiving thrombolytic therapy, adenosine echocardiography identified 12 with viable myocardium as defined by quantitative thallium criteria. | 1793-1961 | 1,793 | 1,961 | In 13 patients receiving thrombolytic therapy, @OBJECT$ @PREDICAT$ @SUBJECT$ identified 12 with viable myocardium as defined by quantitative thallium criteria. |
Possible | preserve | 299-305 | 299-305 | T23 | detect | DIAGNOSES | 299 | 305 | preserve | 213-229 | 213-229 | T12 | echocardiography | DiagnosticProcedure | 213 | 229 | preserve | 306-325 | 315-325 | T16 | ischemic myocardium | DiseaseOrSyndrome | 306 | 325 | A7 | We hypothesized that it would be feasible and safe to use adenosine echocardiography to assess the physiological significance of coronary stenoses, detect ischemic myocardium, and assess myocardial viability in a high risk group of patients with coronary artery disease (CAD). | 139-434 | 139 | 434 | We hypothesized that it would be feasible and safe to use adenosine @SUBJECT$ to assess the physiological significance of coronary stenoses, @PREDICAT$ @OBJECT$ , and assess myocardial viability in a high risk group of patients with coronary artery disease (CAD). |
Fact | preserve | 2075-2077 | 2075-2077 | T127 | of | LOCATION_OF | 2,075 | 2,077 | preserve | 2082-2088 | 2082-2088 | T125 | artery | BodyPartOrganOrOrganComponent | 2,082 | 2,088 | preserve | 2066-2074 | 2066-2074 | T124 | stenosis | PathologicFunction | 2,066 | 2,074 | A8 | Furthermore, the wall-motion response of the viable segment was indicative of the degree of stenosis of the artery subtending the segment. | 1962-2112 | 1,962 | 2,112 | Furthermore, the wall-motion response of the viable segment was indicative of the degree of @OBJECT$ @PREDICAT$ the @SUBJECT$ subtending the segment. |
Fact | preserve | 556-563 | 556-563 | T44 | treated | TREATS | 556 | 563 | preserve | 569-589 | 582-589 | T29 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 569 | 589 | preserve | 528-549 | 539-549 | T28 | myocardial infarction | DiseaseOrSyndrome | 528 | 549 | A9 | Therefore, in 40 patients with either unstable angina, non-Q myocardial infarction, or myocardial infarction treated with thrombolytic therapy, we performed adenosine echocardiography (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. | 435-839 | 435 | 839 | Therefore, in 40 patients with either unstable angina, non-Q myocardial infarction, or @OBJECT$ @PREDICAT$ with @SUBJECT$ , we performed adenosine echocardiography (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. |
Fact | preserve | 461-465 | 461-465 | T43 | with | PROCESS_OF | 461 | 465 | preserve | 479-494 | 488-494 | T26 | unstable angina | DiseaseOrSyndrome | 479 | 494 | preserve | 452-460 | 452-460 | T25 | patients | PatientOrDisabledGroup | 452 | 460 | A10 | Therefore, in 40 patients with either unstable angina, non-Q myocardial infarction, or myocardial infarction treated with thrombolytic therapy, we performed adenosine echocardiography (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. | 435-839 | 435 | 839 | Therefore, in 40 @OBJECT$ @PREDICAT$ either @SUBJECT$ , non-Q myocardial infarction, or myocardial infarction treated with thrombolytic therapy, we performed adenosine echocardiography (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. |
Fact | preserve | 111-137 | 121-137 | T10 | adenosine echocardiography | USES | 111 | 137 | preserve | 121-137 | 121-137 | T8 | echocardiography | DiagnosticProcedure | 121 | 137 | preserve | 111-120 | 111-120 | T7 | adenosine | BiologicallyActiveSubstance | 111 | 120 | A11 | Physiological assessment of coronary artery disease and myocardial viability in ischemic syndromes using adenosine echocardiography. | 0-138 | 0 | 138 | Physiological assessment of coronary artery disease and myocardial viability in ischemic syndromes using @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 2312-2344 | 2328-2344 | T149 | adenosine echocardiography | USES | 2,312 | 2,344 | preserve | 2328-2344 | 2328-2344 | T138 | echocardiography | DiagnosticProcedure | 2,328 | 2,344 | preserve | 2312-2321 | 2312-2321 | T137 | adenosine | BiologicallyActiveSubstance | 2,312 | 2,321 | A12 | Therefore, we conclude that adenosine echocardiography can detect significant coronary stenoses, has a high degree of concordance with thallium in detecting cardiac perfusion abnormalities, and can assess myocardial viability following thrombolytic therapy. | 2284-2559 | 2,284 | 2,559 | Therefore, we conclude that @OBJECT$ @PREDICAT$ @SUBJECT$ can detect significant coronary stenoses, has a high degree of concordance with thallium in detecting cardiac perfusion abnormalities, and can assess myocardial viability following thrombolytic therapy. |
Fact | preserve | 1064-1085 | 1073-1085 | T68 | thallium scintigraphy | USES | 1,064 | 1,085 | preserve | 1073-1085 | 1073-1085 | T63 | scintigraphy | DiagnosticProcedure | 1,073 | 1,085 | preserve | 1064-1072 | 1064-1072 | T62 | thallium | ElementIonOrIsotope | 1,064 | 1,072 | A15 | The sensitivity of adenosine echocardiography and thallium scintigraphy were 96% and 88%, respectively, for detecting greater than 75% stenosis. | 1008-1165 | 1,008 | 1,165 | The sensitivity of adenosine echocardiography and @OBJECT$ @PREDICAT$ @SUBJECT$ were 96% and 88%, respectively, for detecting greater than 75% stenosis. |
Fact | preserve | 197-229 | 213-229 | T22 | adenosine echocardiography | USES | 197 | 229 | preserve | 213-229 | 213-229 | T12 | echocardiography | DiagnosticProcedure | 213 | 229 | preserve | 197-206 | 197-206 | T11 | adenosine | BiologicallyActiveSubstance | 197 | 206 | A16 | We hypothesized that it would be feasible and safe to use adenosine echocardiography to assess the physiological significance of coronary stenoses, detect ischemic myocardium, and assess myocardial viability in a high risk group of patients with coronary artery disease (CAD). | 139-434 | 139 | 434 | We hypothesized that it would be feasible and safe to use @OBJECT$ @PREDICAT$ @SUBJECT$ to assess the physiological significance of coronary stenoses, detect ischemic myocardium, and assess myocardial viability in a high risk group of patients with coronary artery disease (CAD). |
Fact | preserve | 604-630 | 614-630 | T47 | adenosine echocardiography | USES | 604 | 630 | preserve | 614-630 | 614-630 | T31 | echocardiography | DiagnosticProcedure | 614 | 630 | preserve | 604-613 | 604-613 | T30 | adenosine | BiologicallyActiveSubstance | 604 | 613 | A17 | Therefore, in 40 patients with either unstable angina, non-Q myocardial infarction, or myocardial infarction treated with thrombolytic therapy, we performed adenosine echocardiography (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. | 435-839 | 435 | 839 | Therefore, in 40 patients with either unstable angina, non-Q myocardial infarction, or myocardial infarction treated with thrombolytic therapy, we performed @OBJECT$ @PREDICAT$ @SUBJECT$ (140 mug/kg per min for 5 mins with a 16 segment model for analysis) and compared the findings with quantitative planar thallium-201 scintigraphy, and (in 26 patients) coronary angiography. |
Fact | preserve | 399-403 | 399-403 | T24 | with | PROCESS_OF | 399 | 403 | preserve | 404-427 | 420-427 | T21 | coronary artery disease | DiseaseOrSyndrome | 404 | 427 | preserve | 390-398 | 390-398 | T20 | patients | PatientOrDisabledGroup | 390 | 398 | A18 | We hypothesized that it would be feasible and safe to use adenosine echocardiography to assess the physiological significance of coronary stenoses, detect ischemic myocardium, and assess myocardial viability in a high risk group of patients with coronary artery disease (CAD). | 139-434 | 139 | 434 | We hypothesized that it would be feasible and safe to use adenosine echocardiography to assess the physiological significance of coronary stenoses, detect ischemic myocardium, and assess myocardial viability in a high risk group of @OBJECT$ @PREDICAT$ @SUBJECT$ (CAD). |
Fact | preserve | 1808-1817 | 1808-1817 | T118 | receiving | ADMINISTERED_TO | 1,808 | 1,817 | preserve | 1824-1844 | 1837-1844 | T110 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 1,824 | 1,844 | preserve | 1799-1807 | 1799-1807 | T109 | patients | PatientOrDisabledGroup | 1,799 | 1,807 | A20 | In 13 patients receiving thrombolytic therapy, adenosine echocardiography identified 12 with viable myocardium as defined by quantitative thallium criteria. | 1793-1961 | 1,793 | 1,961 | In 13 @OBJECT$ @PREDICAT$ @SUBJECT$ , adenosine echocardiography identified 12 with viable myocardium as defined by quantitative thallium criteria. |
Fact | preserve | 674-682 | 674-682 | T51 | received | ADMINISTERED_TO | 674 | 682 | preserve | 683-693 | 683-693 | T45 | pranlukast | OrganicChemical | 683 | 693 | preserve | 659-667 | 659-667 | T44 | patients | PatientOrDisabledGroup | 659 | 667 | A1 | All patients received pranlukast (225 mg twice daily) for 4 weeks after a 2-week run-in period. | 655-762 | 655 | 762 | All @OBJECT$ @PREDICAT$ @SUBJECT$ (225 mg twice daily) for 4 weeks after a 2-week run-in period. |
Possible | preserve | 1843-1850 | 1843-1850 | T107 | markers | INTERACTS_WITH | 1,843 | 1,850 | preserve | 1796-1805 | 1796-1805 | T100 | PGF1alpha | BiologicallyActiveSubstance | 1,796 | 1,805 | preserve | 1884-1906 | 1896-1906 | T104 | LT-receptor antagonist | OrganicChemical | 1,884 | 1,906 | A2 | CONCLUSIONS: These data suggested that the urinary ratio of LTE4 to 2,3-dinor-6-keto-PGF1alpha might be one of the predictive markers of the clinical efficacy of this LT-receptor antagonist in asthmatic subjects. | 1705-1935 | 1,705 | 1,935 | CONCLUSIONS: These data suggested that the urinary ratio of LTE4 to 2,3-dinor-6-keto- @SUBJECT$ might be one of the predictive @PREDICAT$ of the clinical efficacy of this @OBJECT$ in asthmatic subjects. |
Fact | preserve | 597-615 | 607-615 | T43 | asthmatic patients | PROCESS_OF | 597 | 615 | preserve | 597-606 | 597-606 | T40 | asthmatic | DiseaseOrSyndrome | 597 | 606 | preserve | 607-615 | 607-615 | T41 | patients | PatientOrDisabledGroup | 607 | 615 | A4 | METHODS: An open, multicenter trial was conducted involving 38 stable moderate and severe asthmatic patients (mean percent predicted FEV1 was 71%). | 501-654 | 501 | 654 | METHODS: An open, multicenter trial was conducted involving 38 stable moderate and severe @SUBJECT$ @PREDICAT$ @OBJECT$ (mean percent predicted FEV1 was 71%). |
Fact | preserve | 387-399 | 393-399 | T35 | adult asthma | PROCESS_OF | 387 | 399 | preserve | 393-399 | 393-399 | T28 | asthma | DiseaseOrSyndrome | 393 | 399 | preserve | 387-392 | 387-392 | T27 | adult | AgeGroup | 387 | 392 | A5 | BACKGROUND: To test the hypothesis that urinary levels of arachidonic acid metabolites may be a predicting factor of the effects of pranlukast, a selective leukotriene (LT) antagonist, on chronic adult asthma, we investigated the relationship between its clinical efficacy and urinary eicosanoid levels. | 178-500 | 178 | 500 | BACKGROUND: To test the hypothesis that urinary levels of arachidonic acid metabolites may be a predicting factor of the effects of pranlukast, a selective leukotriene (LT) antagonist, on chronic @OBJECT$ @PREDICAT$ @SUBJECT$ , we investigated the relationship between its clinical efficacy and urinary eicosanoid levels. |
Fact | preserve | 55-57 | 55-57 | T14 | in | TREATS | 55 | 57 | preserve | 0-36 | 26-36 | T1 | Leukotriene (LT)-receptor antagonist | OrganicChemical | 0 | 36 | preserve | 68-76 | 68-76 | T5 | patients | PatientOrDisabledGroup | 68 | 76 | A6 | Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. | 0-177 | 0 | 177 | @SUBJECT$ is more effective @PREDICAT$ asthmatic @OBJECT$ with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. |
Fact | preserve | 58-76 | 68-76 | T13 | asthmatic patients | PROCESS_OF | 58 | 76 | preserve | 58-67 | 58-67 | T4 | asthmatic | DiseaseOrSyndrome | 58 | 67 | preserve | 68-76 | 68-76 | T5 | patients | PatientOrDisabledGroup | 68 | 76 | A7 | Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. | 0-177 | 0 | 177 | Leukotriene (LT)-receptor antagonist is more effective in @SUBJECT$ @PREDICAT$ @OBJECT$ with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. |
Fact | preserve | 55-57 | 55-57 | T14 | in | TREATS | 55 | 57 | preserve | 0-36 | 26-36 | T1 | Leukotriene (LT)-receptor antagonist | OrganicChemical | 0 | 36 | preserve | 58-67 | 58-67 | T4 | asthmatic | DiseaseOrSyndrome | 58 | 67 | A8 | Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. | 0-177 | 0 | 177 | @SUBJECT$ is more effective @PREDICAT$ @OBJECT$ patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. |
Fact | preserve | 531-539 | 531-539 | T40 | produced | CAUSES | 531 | 539 | preserve | 559-567 | 559-567 | T37 | ligation | TherapeuticOrPreventiveProcedure | 559 | 567 | preserve | 505-526 | 516-526 | T34 | Myocardial infarction | DiseaseOrSyndrome | 505 | 526 | A1 | Myocardial infarction was produced by two-stage ligation of the left anterior descending coronary artery. | 505-616 | 505 | 616 | @OBJECT$ was @PREDICAT$ by two-stage @SUBJECT$ of the left anterior descending coronary artery. |
Fact | preserve | 1172-1181 | 1172-1181 | T72 | increased | AUGMENTS | 1,172 | 1,181 | preserve | 1151-1160 | 1151-1160 | T68 | Dothiepin | OrganicChemical | 1,151 | 1,160 | preserve | 1199-1228 | 1217-1228 | T70 | ventricular arrhythmias | PathologicFunction | 1,199 | 1,228 | A2 | Dothiepin at 3 mg/kg increased the incidence of ventricular arrhythmias induced by PES. | 1151-1244 | 1,151 | 1,244 | @SUBJECT$ at 3 mg/kg @PREDICAT$ the incidence of @OBJECT$ induced by PES. |
Probable | preserve | 1631-1638 | 1631-1638 | T98 | effects | AFFECTS | 1,631 | 1,638 | preserve | 1592-1601 | 1592-1601 | T91 | dothiepin | OrganicChemical | 1,592 | 1,601 | preserve | 1642-1668 | 1658-1668 | T95 | cardiac delayed conduction | OrganOrTissueFunction | 1,642 | 1,668 | A4 | These results indicate that dothiepin, 1-3 mg/kg, has lesser effects on cardiac delayed conduction produced by ventricular arrhythmia than amitriptyline. | 1564-1729 | 1,564 | 1,729 | These results indicate that @SUBJECT$ , 1-3 mg/kg, has lesser @PREDICAT$ on @OBJECT$ produced by ventricular arrhythmia than amitriptyline. |
Fact | preserve | 466-471 | 466-471 | T33 | after | PRECEDES | 466 | 471 | preserve | 479-500 | 490-500 | T29 | myocardial infarction | DiseaseOrSyndrome | 479 | 500 | preserve | 373-384 | 373-384 | T23 | arrhythmias | PathologicFunction | 373 | 384 | A5 | In order to clarify the arrhythmogenic effects of antidepressants, the authors examined the effects of dothiepin and amitriptyline on the ventricular activation time (VAT), effective refractory periods(ERP) and incidence of arrhythmias induced by programmed electrical stimulation(PES) in the dog heart in situ after myocardial infarction. | 137-501 | 137 | 501 | In order to clarify the arrhythmogenic effects of antidepressants, the authors examined the effects of dothiepin and amitriptyline on the ventricular activation time (VAT), effective refractory periods(ERP) and incidence of @OBJECT$ induced by programmed electrical stimulation(PES) in the dog heart in situ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 441-443 | 441-443 | T32 | in | LOCATION_OF | 441 | 443 | preserve | 452-457 | 452-457 | T27 | heart | BodyPartOrganOrOrganComponent | 452 | 457 | preserve | 402-435 | 424-435 | T24 | programmed electrical stimulation | DiagnosticProcedure | 402 | 435 | A6 | In order to clarify the arrhythmogenic effects of antidepressants, the authors examined the effects of dothiepin and amitriptyline on the ventricular activation time (VAT), effective refractory periods(ERP) and incidence of arrhythmias induced by programmed electrical stimulation(PES) in the dog heart in situ after myocardial infarction. | 137-501 | 137 | 501 | In order to clarify the arrhythmogenic effects of antidepressants, the authors examined the effects of dothiepin and amitriptyline on the ventricular activation time (VAT), effective refractory periods(ERP) and incidence of arrhythmias induced by @OBJECT$ (PES) @PREDICAT$ the dog @SUBJECT$ in situ after myocardial infarction. |
Fact | preserve | 78-80 | 78-80 | T9 | in | LOCATION_OF | 78 | 80 | preserve | 99-104 | 99-104 | T6 | heart | BodyPartOrganOrOrganComponent | 99 | 104 | preserve | 55-77 | 67-77 | T4 | ventricular arrhythmia | PathologicFunction | 55 | 77 | A7 | Effects of dothiepin on delayed conduction produced by ventricular arrhythmia in the canine heart after myocardial infarction. | 0-133 | 0 | 133 | Effects of dothiepin on delayed conduction produced by @OBJECT$ @PREDICAT$ the canine @SUBJECT$ after myocardial infarction. |
Fact | preserve | 92-104 | 99-104 | T8 | canine heart | PART_OF | 92 | 104 | preserve | 99-104 | 99-104 | T6 | heart | BodyPartOrganOrOrganComponent | 99 | 104 | preserve | 92-98 | 92-98 | T5 | canine | Mammal | 92 | 98 | A8 | Effects of dothiepin on delayed conduction produced by ventricular arrhythmia in the canine heart after myocardial infarction. | 0-133 | 0 | 133 | Effects of dothiepin on delayed conduction produced by ventricular arrhythmia in the @OBJECT$ @PREDICAT$ @SUBJECT$ after myocardial infarction. |
Fact | preserve | 105-110 | 105-110 | T10 | after | PRECEDES | 105 | 110 | preserve | 111-132 | 122-132 | T7 | myocardial infarction | DiseaseOrSyndrome | 111 | 132 | preserve | 55-77 | 67-77 | T4 | ventricular arrhythmia | PathologicFunction | 55 | 77 | A9 | Effects of dothiepin on delayed conduction produced by ventricular arrhythmia in the canine heart after myocardial infarction. | 0-133 | 0 | 133 | Effects of dothiepin on delayed conduction produced by @OBJECT$ in the canine heart @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1496-1505 | 1496-1505 | T89 | increased | AUGMENTS | 1,496 | 1,505 | preserve | 1460-1473 | 1460-1473 | T84 | Amitriptyline | OrganicChemical | 1,460 | 1,473 | preserve | 1523-1552 | 1541-1552 | T87 | ventricular arrhythmias | PathologicFunction | 1,523 | 1,552 | A10 | Amitriptyline at doses of 1-3 mg/kg increased the incidence of ventricular arrhythmias by PES. | 1460-1560 | 1,460 | 1,560 | @SUBJECT$ at doses of 1-3 mg/kg @PREDICAT$ the incidence of @OBJECT$ by PES. |
Fact | preserve | 448-457 | 452-457 | T31 | dog heart | PART_OF | 448 | 457 | preserve | 452-457 | 452-457 | T27 | heart | BodyPartOrganOrOrganComponent | 452 | 457 | preserve | 448-451 | 448-451 | T26 | dog | Mammal | 448 | 451 | A11 | In order to clarify the arrhythmogenic effects of antidepressants, the authors examined the effects of dothiepin and amitriptyline on the ventricular activation time (VAT), effective refractory periods(ERP) and incidence of arrhythmias induced by programmed electrical stimulation(PES) in the dog heart in situ after myocardial infarction. | 137-501 | 137 | 501 | In order to clarify the arrhythmogenic effects of antidepressants, the authors examined the effects of dothiepin and amitriptyline on the ventricular activation time (VAT), effective refractory periods(ERP) and incidence of arrhythmias induced by programmed electrical stimulation(PES) in the @OBJECT$ @PREDICAT$ @SUBJECT$ in situ after myocardial infarction. |
Fact | preserve | 700-703 | 700-703 | T48 | for | USES | 700 | 703 | preserve | 708-718 | 708-718 | T46 | prevention | TherapeuticOrPreventiveProcedure | 708 | 718 | preserve | 673-678 | 673-678 | T44 | drugs | PharmacologicSubstance | 673 | 678 | A1 | A continuation study also showed that sustained remission rates were higher with mirtazapine than with amitriptyline and that the drugs had similar efficacy for the prevention of relapse. | 531-736 | 531 | 736 | A continuation study also showed that sustained remission rates were higher with mirtazapine than with amitriptyline and that the @OBJECT$ had similar efficacy @PREDICAT$ the @SUBJECT$ of relapse. |
Fact | preserve | 1264-1268 | 1264-1268 | T86 | with | PROCESS_OF | 1,264 | 1,268 | preserve | 1280-1290 | 1280-1290 | T83 | depression | MentalOrBehavioralDysfunction | 1,280 | 1,290 | preserve | 1255-1263 | 1255-1263 | T81 | patients | PatientOrDisabledGroup | 1,255 | 1,263 | A2 | Preliminary data suggest that the drug may be effective as an augmentation or combination therapy in patients with refractory depression. | 1141-1291 | 1,141 | 1,291 | Preliminary data suggest that the drug may be effective as an augmentation or combination therapy in @OBJECT$ @PREDICAT$ refractory @SUBJECT$ . |
Possible | preserve | 1252-1254 | 1252-1254 | T84 | in | TREATS | 1,252 | 1,254 | preserve | 1209-1221 | 1209-1221 | T79 | augmentation | TherapeuticOrPreventiveProcedure | 1,209 | 1,221 | preserve | 1255-1263 | 1255-1263 | T81 | patients | PatientOrDisabledGroup | 1,255 | 1,263 | A4 | Preliminary data suggest that the drug may be effective as an augmentation or combination therapy in patients with refractory depression. | 1141-1291 | 1,141 | 1,291 | Preliminary data suggest that the drug may be effective as an @SUBJECT$ or combination therapy @PREDICAT$ @OBJECT$ with refractory depression. |
Fact | preserve | 1907-1918 | 1907-1918 | T130 | metabolised | INTERACTS_WITH | 1,907 | 1,918 | preserve | 1928-1952 | 1949-1952 | T123 | cytochrome P450 (CYP)2D6 | AminoAcidPeptideOrProtein | 1,928 | 1,952 | preserve | 1901-1906 | 1901-1906 | T122 | drugs | PharmacologicSubstance | 1,901 | 1,906 | A6 | In vitro and in vivo data have suggested that mirtazapine is unlikely to affect the metabolism of drugs metabolised by cytochrome P450 (CYP)2D6, although few formal drug interaction data are available. | 1797-2016 | 1,797 | 2,016 | In vitro and in vivo data have suggested that mirtazapine is unlikely to affect the metabolism of @OBJECT$ @PREDICAT$ by @SUBJECT$ , although few formal drug interaction data are available. |
Possible | preserve | 1252-1254 | 1252-1254 | T84 | in | TREATS | 1,252 | 1,254 | preserve | 1209-1221 | 1209-1221 | T79 | augmentation | TherapeuticOrPreventiveProcedure | 1,209 | 1,221 | preserve | 1280-1290 | 1280-1290 | T83 | depression | MentalOrBehavioralDysfunction | 1,280 | 1,290 | A7 | Preliminary data suggest that the drug may be effective as an augmentation or combination therapy in patients with refractory depression. | 1141-1291 | 1,141 | 1,291 | Preliminary data suggest that the drug may be effective as an @SUBJECT$ or combination therapy @PREDICAT$ patients with refractory @OBJECT$ . |
Fact | preserve | 456-460 | 456-460 | T33 | with | PROCESS_OF | 456 | 460 | preserve | 470-492 | 484-492 | T23 | anxiety symptoms | Finding | 470 | 492 | preserve | 389-397 | 389-397 | T20 | patients | PatientOrDisabledGroup | 389 | 397 | A8 | The drug had equivalent efficacy to tricyclic antidepressants and it was at least as effective as trazodone in the majority of available short term trials in patients with moderate or severe depression, including those with baseline anxiety symptoms or sleep disturbance and the elderly. | 217-530 | 217 | 530 | The drug had equivalent efficacy to tricyclic antidepressants and it was at least as effective as trazodone in the majority of available short term trials in @OBJECT$ with moderate or severe depression, including those @PREDICAT$ baseline @SUBJECT$ or sleep disturbance and the elderly. |
Fact | preserve | 940-944 | 940-944 | T72 | than | higher_than | 940 | 944 | preserve | 909-920 | 909-920 | T56 | Mirtazapine | OrganicChemical | 909 | 920 | preserve | 954-964 | 954-964 | T59 | fluoxetine | OrganicChemical | 954 | 964 | A9 | Mirtazapine was more effective than the SSRI fluoxetine at weeks 3 and 4 of therapy and it was also more effective than paroxetine and citalopram at weeks 1 and 2, respectively, in short term assessments (6 or 8 weeks). | 909-1140 | 909 | 1,140 | @SUBJECT$ was more effective @PREDICAT$ the SSRI @OBJECT$ at weeks 3 and 4 of therapy and it was also more effective than paroxetine and citalopram at weeks 1 and 2, respectively, in short term assessments (6 or 8 weeks). |
Fact | preserve | 2932-2936 | 2932-2936 | T181 | with | PROCESS_OF | 2,932 | 2,936 | preserve | 2943-2953 | 2943-2953 | T177 | depression | MentalOrBehavioralDysfunction | 2,943 | 2,953 | preserve | 2923-2931 | 2923-2931 | T176 | patients | PatientOrDisabledGroup | 2,923 | 2,931 | A10 | Mirtazapine also appears to be useful in patients with depression who present with anxiety symptoms and sleep disturbance. | 2882-3010 | 2,882 | 3,010 | Mirtazapine also appears to be useful in @OBJECT$ @PREDICAT$ @SUBJECT$ who present with anxiety symptoms and sleep disturbance. |
Fact | preserve | 2088-2097 | 2088-2097 | T138 | treatment | TREATS | 2,088 | 2,097 | preserve | 2030-2041 | 2030-2041 | T131 | Mirtazapine | OrganicChemical | 2,030 | 2,041 | preserve | 2101-2109 | 2101-2109 | T135 | patients | PatientOrDisabledGroup | 2,101 | 2,109 | A15 | CONCLUSIONS: Mirtazapine is effective and well tolerated for the treatment of patients with moderate to severe major depression. | 2017-2151 | 2,017 | 2,151 | CONCLUSIONS: @SUBJECT$ is effective and well tolerated for the @PREDICAT$ of @OBJECT$ with moderate to severe major depression. |
Fact | preserve | 2408-2412 | 2408-2412 | T159 | with | PROCESS_OF | 2,408 | 2,412 | preserve | 2430-2440 | 2430-2440 | T151 | depression | MentalOrBehavioralDysfunction | 2,430 | 2,440 | preserve | 2399-2407 | 2399-2407 | T149 | patients | PatientOrDisabledGroup | 2,399 | 2,407 | A16 | Clarification of its efficacy as an augmentation therapy and in patients with refractory depression and its role in improving the efficacy and reducing the extrapyramidal effects of antipsychotic drugs would also help to establish its clinical value. | 2328-2597 | 2,328 | 2,597 | Clarification of its efficacy as an augmentation therapy and in @OBJECT$ @PREDICAT$ refractory @SUBJECT$ and its role in improving the efficacy and reducing the extrapyramidal effects of antipsychotic drugs would also help to establish its clinical value. |
Fact | preserve | 2371-2391 | 2384-2391 | T158 | augmentation therapy | ISA | 2,371 | 2,391 | preserve | 2371-2383 | 2371-2383 | T147 | augmentation | TherapeuticOrPreventiveProcedure | 2,371 | 2,383 | preserve | 2384-2391 | 2384-2391 | T148 | therapy | TherapeuticOrPreventiveProcedure | 2,384 | 2,391 | A18 | Clarification of its efficacy as an augmentation therapy and in patients with refractory depression and its role in improving the efficacy and reducing the extrapyramidal effects of antipsychotic drugs would also help to establish its clinical value. | 2328-2597 | 2,328 | 2,597 | Clarification of its efficacy as an @SUBJECT$ @PREDICAT$ @OBJECT$ and in patients with refractory depression and its role in improving the efficacy and reducing the extrapyramidal effects of antipsychotic drugs would also help to establish its clinical value. |
Doubtful | preserve | 1876-1882 | 1876-1882 | T129 | affect | INTERACTS_WITH | 1,876 | 1,882 | preserve | 1849-1860 | 1849-1860 | T120 | mirtazapine | OrganicChemical | 1,849 | 1,860 | preserve | 1901-1906 | 1901-1906 | T122 | drugs | PharmacologicSubstance | 1,901 | 1,906 | A20 | In vitro and in vivo data have suggested that mirtazapine is unlikely to affect the metabolism of drugs metabolised by cytochrome P450 (CYP)2D6, although few formal drug interaction data are available. | 1797-2016 | 1,797 | 2,016 | In vitro and in vivo data have suggested that @SUBJECT$ is unlikely to @PREDICAT$ the metabolism of @OBJECT$ metabolised by cytochrome P450 (CYP)2D6, although few formal drug interaction data are available. |
Possible | preserve | 1252-1254 | 1252-1254 | T84 | in | TREATS | 1,252 | 1,254 | preserve | 1225-1244 | 1237-1244 | T80 | combination therapy | TherapeuticOrPreventiveProcedure | 1,225 | 1,244 | preserve | 1280-1290 | 1280-1290 | T83 | depression | MentalOrBehavioralDysfunction | 1,280 | 1,290 | A21 | Preliminary data suggest that the drug may be effective as an augmentation or combination therapy in patients with refractory depression. | 1141-1291 | 1,141 | 1,291 | Preliminary data suggest that the drug may be effective as an augmentation or @SUBJECT$ @PREDICAT$ patients with refractory @OBJECT$ . |
Fact | preserve | 2839-2841 | 2839-2841 | T174 | in | PROCESS_OF | 2,839 | 2,841 | preserve | 2822-2838 | 2828-2838 | T170 | major depression | MentalOrBehavioralDysfunction | 2,822 | 2,838 | preserve | 2842-2850 | 2842-2850 | T171 | patients | PatientOrDisabledGroup | 2,842 | 2,850 | A22 | The low potential for interaction with drugs that are metabolised by CYP2D6, including antipsychotics, tricyclic antidepressants and some SSRIs, may also make mirtazapine an important option for the treatment of major depression in patients who require polytherapy. | 2598-2881 | 2,598 | 2,881 | The low potential for interaction with drugs that are metabolised by CYP2D6, including antipsychotics, tricyclic antidepressants and some SSRIs, may also make mirtazapine an important option for the treatment of @SUBJECT$ @PREDICAT$ @OBJECT$ who require polytherapy. |
Possible | preserve | 1252-1254 | 1252-1254 | T84 | in | TREATS | 1,252 | 1,254 | preserve | 1225-1244 | 1237-1244 | T80 | combination therapy | TherapeuticOrPreventiveProcedure | 1,225 | 1,244 | preserve | 1255-1263 | 1255-1263 | T81 | patients | PatientOrDisabledGroup | 1,255 | 1,263 | A23 | Preliminary data suggest that the drug may be effective as an augmentation or combination therapy in patients with refractory depression. | 1141-1291 | 1,141 | 1,291 | Preliminary data suggest that the drug may be effective as an augmentation or @SUBJECT$ @PREDICAT$ @OBJECT$ with refractory depression. |
Probable | preserve | 2920-2922 | 2920-2922 | T180 | in | TREATS | 2,920 | 2,922 | preserve | 2882-2893 | 2882-2893 | T175 | Mirtazapine | OrganicChemical | 2,882 | 2,893 | preserve | 2923-2931 | 2923-2931 | T176 | patients | PatientOrDisabledGroup | 2,923 | 2,931 | A24 | Mirtazapine also appears to be useful in patients with depression who present with anxiety symptoms and sleep disturbance. | 2882-3010 | 2,882 | 3,010 | @SUBJECT$ also appears to be useful @PREDICAT$ @OBJECT$ with depression who present with anxiety symptoms and sleep disturbance. |
Fact | preserve | 33-35 | 33-35 | T4 | in | TREATS | 33 | 35 | preserve | 0-11 | 0-11 | T1 | Mirtazapine | OrganicChemical | 0 | 11 | preserve | 36-52 | 42-52 | T3 | major depression | MentalOrBehavioralDysfunction | 36 | 52 | A27 | Mirtazapine: a review of its use in major depression. | 0-53 | 0 | 53 | @SUBJECT$ : a review of its use @PREDICAT$ @OBJECT$ . |
Probable | preserve | 2809-2818 | 2809-2818 | T173 | treatment | TREATS | 2,809 | 2,818 | preserve | 2769-2780 | 2769-2780 | T167 | mirtazapine | OrganicChemical | 2,769 | 2,780 | preserve | 2822-2838 | 2828-2838 | T170 | major depression | MentalOrBehavioralDysfunction | 2,822 | 2,838 | A28 | The low potential for interaction with drugs that are metabolised by CYP2D6, including antipsychotics, tricyclic antidepressants and some SSRIs, may also make mirtazapine an important option for the treatment of major depression in patients who require polytherapy. | 2598-2881 | 2,598 | 2,881 | The low potential for interaction with drugs that are metabolised by CYP2D6, including antipsychotics, tricyclic antidepressants and some SSRIs, may also make @SUBJECT$ an important option for the @PREDICAT$ of @OBJECT$ in patients who require polytherapy. |
Fact | preserve | 456-460 | 456-460 | T33 | with | PROCESS_OF | 456 | 460 | preserve | 496-513 | 502-513 | T24 | sleep disturbance | DiseaseOrSyndrome | 496 | 513 | preserve | 389-397 | 389-397 | T20 | patients | PatientOrDisabledGroup | 389 | 397 | A30 | The drug had equivalent efficacy to tricyclic antidepressants and it was at least as effective as trazodone in the majority of available short term trials in patients with moderate or severe depression, including those with baseline anxiety symptoms or sleep disturbance and the elderly. | 217-530 | 217 | 530 | The drug had equivalent efficacy to tricyclic antidepressants and it was at least as effective as trazodone in the majority of available short term trials in @OBJECT$ with moderate or severe depression, including those @PREDICAT$ baseline anxiety symptoms or @SUBJECT$ and the elderly. |
Probable | preserve | 2920-2922 | 2920-2922 | T180 | in | TREATS | 2,920 | 2,922 | preserve | 2882-2893 | 2882-2893 | T175 | Mirtazapine | OrganicChemical | 2,882 | 2,893 | preserve | 2943-2953 | 2943-2953 | T177 | depression | MentalOrBehavioralDysfunction | 2,943 | 2,953 | A34 | Mirtazapine also appears to be useful in patients with depression who present with anxiety symptoms and sleep disturbance. | 2882-3010 | 2,882 | 3,010 | @SUBJECT$ also appears to be useful @PREDICAT$ patients with @OBJECT$ who present with anxiety symptoms and sleep disturbance. |
Fact | preserve | 2652-2663 | 2652-2663 | T172 | metabolised | INTERACTS_WITH | 2,652 | 2,663 | preserve | 2667-2673 | 2667-2673 | T164 | CYP2D6 | GeneOrGenome | 2,667 | 2,673 | preserve | 2637-2642 | 2637-2642 | T163 | drugs | PharmacologicSubstance | 2,637 | 2,642 | A35 | The low potential for interaction with drugs that are metabolised by CYP2D6, including antipsychotics, tricyclic antidepressants and some SSRIs, may also make mirtazapine an important option for the treatment of major depression in patients who require polytherapy. | 2598-2881 | 2,598 | 2,881 | The low potential for interaction with @OBJECT$ that are @PREDICAT$ by @SUBJECT$ , including antipsychotics, tricyclic antidepressants and some SSRIs, may also make mirtazapine an important option for the treatment of major depression in patients who require polytherapy. |
Fact | preserve | 940-944 | 940-944 | T71 | than | compared_with | 940 | 944 | preserve | 909-920 | 909-920 | T56 | Mirtazapine | OrganicChemical | 909 | 920 | preserve | 954-964 | 954-964 | T59 | fluoxetine | OrganicChemical | 954 | 964 | A36 | Mirtazapine was more effective than the SSRI fluoxetine at weeks 3 and 4 of therapy and it was also more effective than paroxetine and citalopram at weeks 1 and 2, respectively, in short term assessments (6 or 8 weeks). | 909-1140 | 909 | 1,140 | @SUBJECT$ was more effective @PREDICAT$ the SSRI @OBJECT$ at weeks 3 and 4 of therapy and it was also more effective than paroxetine and citalopram at weeks 1 and 2, respectively, in short term assessments (6 or 8 weeks). |
Fact | preserve | 3151-3153 | 3151-3153 | T184 | in | PROCESS_OF | 3,151 | 3,153 | preserve | 3121-3130 | 3125-3130 | T169 | hay fever | DiseaseOrSyndrome | 3,121 | 3,130 | preserve | 3160-3168 | 3160-3168 | T171 | patients | PatientOrDisabledGroup | 3,160 | 3,168 | A1 | These results highlight the different environmental risk factors for hay fever and allergic asthma in patients, as on days of rainfall following high grass pollen count, the risk for asthma sufferers is far greater than on days of high pollen count with no associated rainfall. | 3046-3348 | 3,046 | 3,348 | These results highlight the different environmental risk factors for @SUBJECT$ and allergic asthma @PREDICAT$ @OBJECT$ , as on days of rainfall following high grass pollen count, the risk for asthma sufferers is far greater than on days of high pollen count with no associated rainfall. |
Fact | preserve | 1730-1732 | 1730-1732 | T107 | in | COEXISTS_WITH | 1,730 | 1,732 | preserve | 1720-1729 | 1720-1729 | T98 | allergens | ImmunologicFactor | 1,720 | 1,729 | preserve | 1746-1761 | 1753-1761 | T101 | pollen extracts | OrganicChemical | 1,746 | 1,761 | A2 | RESULTS: Phl p 5-specific MoAb detected group 5 allergens in tested grass pollen extracts, indicating that the ELISA employed here determines total group 5 allergen concentrations. | 1666-1858 | 1,666 | 1,858 | RESULTS: Phl p 5-specific MoAb detected group 5 @SUBJECT$ @PREDICAT$ tested grass @OBJECT$ , indicating that the ELISA employed here determines total group 5 allergen concentrations. |
Fact | preserve | 258-263 | 258-263 | T22 | cause | CAUSES | 258 | 263 | preserve | 212-234 | 225-234 | T14 | Grass pollen allergens | ImmunologicFactor | 212 | 234 | preserve | 288-303 | 297-303 | T18 | allergic asthma | DiseaseOrSyndrome | 288 | 303 | A6 | BACKGROUND: Grass pollen allergens are the most important cause of hay fever and allergic asthma during summer in cool temperate climates. | 200-345 | 200 | 345 | BACKGROUND: @SUBJECT$ are the most important @PREDICAT$ of hay fever and @OBJECT$ during summer in cool temperate climates. |
Fact | preserve | 3634-3641 | 3634-3641 | T202 | trigger | CAUSES | 3,634 | 3,641 | preserve | 3581-3591 | 3581-3591 | T194 | pollutants | HazardousOrPoisonousSubstance | 3,581 | 3,591 | preserve | 3642-3657 | 3651-3657 | T199 | allergic asthma | DiseaseOrSyndrome | 3,642 | 3,657 | A8 | diesel exhaust carbon particles) to trigger allergic asthma. | 3598-3658 | 3,598 | 3,658 | diesel exhaust carbon particles) to trigger @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1740-1761 | 1753-1761 | T106 | grass pollen extracts | LOCATION_OF | 1,740 | 1,761 | preserve | 1740-1745 | 1740-1745 | T100 | grass | Plant | 1,740 | 1,745 | preserve | 1746-1761 | 1753-1761 | T101 | pollen extracts | OrganicChemical | 1,746 | 1,761 | A12 | RESULTS: Phl p 5-specific MoAb detected group 5 allergens in tested grass pollen extracts, indicating that the ELISA employed here determines total group 5 allergen concentrations. | 1666-1858 | 1,666 | 1,858 | RESULTS: Phl p 5-specific MoAb detected group 5 allergens in tested @SUBJECT$ @PREDICAT$ @OBJECT$ , indicating that the ELISA employed here determines total group 5 allergen concentrations. |
Fact | preserve | 3151-3153 | 3151-3153 | T184 | in | PROCESS_OF | 3,151 | 3,153 | preserve | 3135-3150 | 3144-3150 | T170 | allergic asthma | DiseaseOrSyndrome | 3,135 | 3,150 | preserve | 3160-3168 | 3160-3168 | T171 | patients | PatientOrDisabledGroup | 3,160 | 3,168 | A13 | These results highlight the different environmental risk factors for hay fever and allergic asthma in patients, as on days of rainfall following high grass pollen count, the risk for asthma sufferers is far greater than on days of high pollen count with no associated rainfall. | 3046-3348 | 3,046 | 3,348 | These results highlight the different environmental risk factors for hay fever and @SUBJECT$ @PREDICAT$ @OBJECT$ , as on days of rainfall following high grass pollen count, the risk for asthma sufferers is far greater than on days of high pollen count with no associated rainfall. |
Fact | preserve | 258-263 | 258-263 | T22 | cause | CAUSES | 258 | 263 | preserve | 212-234 | 225-234 | T14 | Grass pollen allergens | ImmunologicFactor | 212 | 234 | preserve | 267-276 | 271-276 | T17 | hay fever | DiseaseOrSyndrome | 267 | 276 | A15 | BACKGROUND: Grass pollen allergens are the most important cause of hay fever and allergic asthma during summer in cool temperate climates. | 200-345 | 200 | 345 | BACKGROUND: @SUBJECT$ are the most important @PREDICAT$ of @OBJECT$ and allergic asthma during summer in cool temperate climates. |
Fact | preserve | 1578-1580 | 1578-1580 | T92 | in | COEXISTS_WITH | 1,578 | 1,580 | preserve | 1568-1577 | 1568-1577 | T86 | allergens | ImmunologicFactor | 1,568 | 1,577 | preserve | 1581-1596 | 1588-1596 | T87 | pollen extracts | OrganicChemical | 1,581 | 1,596 | A16 | A MoAb-based ELISA was then employed to quantify Phl p 5 and cross-reactive allergens in pollen extracts and atmospheric particles larger and smaller than 7.2 microm. | 1486-1665 | 1,486 | 1,665 | A MoAb-based ELISA was then employed to quantify Phl p 5 and cross-reactive @SUBJECT$ @PREDICAT$ @OBJECT$ and atmospheric particles larger and smaller than 7.2 microm. |
Fact | preserve | 3422-3426 | 3422-3426 | T200 | from | LOCATION_OF | 3,422 | 3,426 | preserve | 3427-3440 | 3434-3440 | T187 | fungal spores | Fungus | 3,427 | 3,440 | preserve | 3412-3421 | 3412-3421 | T186 | allergens | ImmunologicFactor | 3,412 | 3,421 | A18 | Moreover, rainfall may also contribute to the release of allergens from fungal spores and, along with the release of free allergen molecules from pollen grains, may be able to interact with other particles such as pollutants (i.e. | 3349-3597 | 3,349 | 3,597 | Moreover, rainfall may also contribute to the release of @OBJECT$ @PREDICAT$ @SUBJECT$ and, along with the release of free allergen molecules from pollen grains, may be able to interact with other particles such as pollutants (i.e. |
Fact | preserve | 1132-1159 | 1146-1159 | T62 | blood glucose concentration | LOCATION_OF | 1,132 | 1,159 | preserve | 1132-1137 | 1132-1137 | T57 | blood | Tissue | 1,132 | 1,137 | preserve | 1138-1159 | 1146-1159 | T58 | glucose concentration | LaboratoryProcedure | 1,138 | 1,159 | A1 | The glycemic threshold to prevent the onset and progression of diabetic microvascular complications in the Kumamoto Study was indicated as follows; HbA1c < 6.5%, fasting blood glucose concentration < 110 mg/dl, and 2-hour postprandial blood glucose concentration < 180 mg/dl. | 949-1243 | 949 | 1,243 | The glycemic threshold to prevent the onset and progression of diabetic microvascular complications in the Kumamoto Study was indicated as follows; HbA1c < 6.5%, fasting @SUBJECT$ @PREDICAT$ @OBJECT$ < 110 mg/dl, and 2-hour postprandial blood glucose concentration < 180 mg/dl. |
Fact | preserve | 605-621 | 612-621 | T45 | B cell functions | LOCATION_OF | 605 | 621 | preserve | 605-611 | 607-611 | T28 | B cell | Cell | 605 | 611 | preserve | 596-621 | 612-621 | T29 | residual B cell functions | DiagnosticProcedure | 596 | 621 | A2 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose residual B cell functions are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. | 401-948 | 401 | 948 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose @OBJECT$ @SUBJECT$ @PREDICAT$ are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose residual B cell functions are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. |
Fact | preserve | 767-771 | 767-771 | T46 | with | PROCESS_OF | 767 | 771 | preserve | 772-810 | 802-810 | T37 | noninsulin dependent diabetes mellitus | DiseaseOrSyndrome | 772 | 810 | preserve | 758-766 | 758-766 | T36 | patients | PatientOrDisabledGroup | 758 | 766 | A3 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose residual B cell functions are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. | 401-948 | 401 | 948 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the @OBJECT$ @PREDICAT$ @SUBJECT$ whose residual B cell functions are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. |
Fact | preserve | 353-357 | 353-357 | T20 | with | PROCESS_OF | 353 | 357 | preserve | 358-399 | 391-399 | T16 | insulin dependent diabetes mellitus | DiseaseOrSyndrome | 358 | 399 | preserve | 344-352 | 344-352 | T15 | patients | PatientOrDisabledGroup | 344 | 352 | A4 | DCCT and Kumamoto Study demonstrated that optimal glycemic control with intensive insulin therapy could delay the onset and progression of the early stages of diabetic microvascular complications in Japanese patients with noninsulin dependent diabetes as well as in patients with insulin dependent diabetes mellitus. | 60-400 | 60 | 400 | DCCT and Kumamoto Study demonstrated that optimal glycemic control with intensive insulin therapy could delay the onset and progression of the early stages of diabetic microvascular complications in Japanese patients with noninsulin dependent diabetes as well as in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 900-904 | 900-904 | T48 | with | PROCESS_OF | 900 | 904 | preserve | 912-947 | 939-947 | T42 | insulin dependent diabetes mellitus | DiseaseOrSyndrome | 912 | 947 | preserve | 891-899 | 891-899 | T41 | patients | PatientOrDisabledGroup | 891 | 899 | A5 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose residual B cell functions are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. | 401-948 | 401 | 948 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose residual B cell functions are severely exhausted as well as in the @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 540-544 | 540-544 | T44 | with | PROCESS_OF | 540 | 544 | preserve | 545-589 | 581-589 | T27 | noninsulin dependent diabetes mellitus | DiseaseOrSyndrome | 545 | 589 | preserve | 531-539 | 531-539 | T26 | patients | PatientOrDisabledGroup | 531 | 539 | A6 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose residual B cell functions are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. | 401-948 | 401 | 948 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring @OBJECT$ @PREDICAT$ @SUBJECT$ whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose residual B cell functions are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. |
Fact | preserve | 289-293 | 289-293 | T18 | with | PROCESS_OF | 289 | 293 | preserve | 294-329 | 321-329 | T14 | noninsulin dependent diabetes | DiseaseOrSyndrome | 294 | 329 | preserve | 280-288 | 280-288 | T13 | patients | PatientOrDisabledGroup | 280 | 288 | A8 | DCCT and Kumamoto Study demonstrated that optimal glycemic control with intensive insulin therapy could delay the onset and progression of the early stages of diabetic microvascular complications in Japanese patients with noninsulin dependent diabetes as well as in patients with insulin dependent diabetes mellitus. | 60-400 | 60 | 400 | DCCT and Kumamoto Study demonstrated that optimal glycemic control with intensive insulin therapy could delay the onset and progression of the early stages of diabetic microvascular complications in Japanese @OBJECT$ @PREDICAT$ @SUBJECT$ as well as in patients with insulin dependent diabetes mellitus. |
Fact | preserve | 268-270 | 268-270 | T17 | in | PROCESS_OF | 268 | 270 | preserve | 231-267 | 254-267 | T12 | diabetic microvascular complications | DiseaseOrSyndrome | 231 | 267 | preserve | 280-288 | 280-288 | T13 | patients | PatientOrDisabledGroup | 280 | 288 | A10 | DCCT and Kumamoto Study demonstrated that optimal glycemic control with intensive insulin therapy could delay the onset and progression of the early stages of diabetic microvascular complications in Japanese patients with noninsulin dependent diabetes as well as in patients with insulin dependent diabetes mellitus. | 60-400 | 60 | 400 | DCCT and Kumamoto Study demonstrated that optimal glycemic control with intensive insulin therapy could delay the onset and progression of the early stages of @SUBJECT$ @PREDICAT$ Japanese @OBJECT$ with noninsulin dependent diabetes as well as in patients with insulin dependent diabetes mellitus. |
Fact | preserve | 1203-1230 | 1217-1230 | T63 | blood glucose concentration | LOCATION_OF | 1,203 | 1,230 | preserve | 1203-1208 | 1203-1208 | T60 | blood | Tissue | 1,203 | 1,208 | preserve | 1209-1230 | 1217-1230 | T61 | glucose concentration | LaboratoryProcedure | 1,209 | 1,230 | A11 | The glycemic threshold to prevent the onset and progression of diabetic microvascular complications in the Kumamoto Study was indicated as follows; HbA1c < 6.5%, fasting blood glucose concentration < 110 mg/dl, and 2-hour postprandial blood glucose concentration < 180 mg/dl. | 949-1243 | 949 | 1,243 | The glycemic threshold to prevent the onset and progression of diabetic microvascular complications in the Kumamoto Study was indicated as follows; HbA1c < 6.5%, fasting blood glucose concentration < 110 mg/dl, and 2-hour postprandial @SUBJECT$ @PREDICAT$ @OBJECT$ < 180 mg/dl. |
Fact | preserve | 833-849 | 840-849 | T47 | B cell functions | LOCATION_OF | 833 | 849 | preserve | 833-839 | 835-839 | T38 | B cell | Cell | 833 | 839 | preserve | 824-849 | 840-849 | T39 | residual B cell functions | DiagnosticProcedure | 824 | 849 | A13 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose residual B cell functions are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. | 401-948 | 401 | 948 | To obtain optimal glycemic control, the prandial insulin supplements before each meal are recommended for insulin requiring patients with noninsulin dependent diabetes mellitus whose residual B cell functions are retained to some extent, whereas the combined basal at bedtime plus prandial insulin supplements are essential for the patients with noninsulin dependent diabetes mellitus whose @OBJECT$ @SUBJECT$ @PREDICAT$ are severely exhausted as well as in the patients with insulin dependent diabetes mellitus. |
Fact | preserve | 980-999 | 989-999 | T71 | diseased myocardium | PROCESS_OF | 980 | 999 | preserve | 980-988 | 980-988 | T69 | diseased | DiseaseOrSyndrome | 980 | 988 | preserve | 989-999 | 989-999 | T70 | myocardium | Tissue | 989 | 999 | A1 | Differences in concentration of TR alpha 2 mRNA among the 3 groups of dogs were not detected, but concentrations of TR beta 1 and beta 2 mRNA were greater in diseased myocardium. | 810-1000 | 810 | 1,000 | Differences in concentration of TR alpha 2 mRNA among the 3 groups of dogs were not detected, but concentrations of TR beta 1 and beta 2 mRNA were greater in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 516-522 | 516-522 | T43 | caused | CAUSES | 516 | 522 | preserve | 561-591 | 584-591 | T39 | chronic valvular disease | DiseaseOrSyndrome | 561 | 591 | preserve | 502-515 | 508-515 | T36 | heart failure | DiseaseOrSyndrome | 502 | 515 | A3 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and dogs with heart failure caused by dilated cardiomyopathy (DCM; 7) or chronic valvular disease (CVD; 7). | 342-601 | 342 | 601 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and dogs with @OBJECT$ @PREDICAT$ by dilated cardiomyopathy (DCM; 7) or @SUBJECT$ (CVD; 7). |
Fact | preserve | 304-308 | 304-308 | T23 | with | PROCESS_OF | 304 | 308 | preserve | 309-322 | 315-322 | T20 | heart failure | DiseaseOrSyndrome | 309 | 322 | preserve | 299-303 | 299-303 | T19 | dogs | Mammal | 299 | 303 | A5 | OBJECTIVE: To investigate whether expression of thyroid hormone receptor (TR) messenger RNA (mRNA) is changed in the myocardium of dogs with heart failure. | 162-323 | 162 | 323 | OBJECTIVE: To investigate whether expression of thyroid hormone receptor (TR) messenger RNA (mRNA) is changed in the myocardium of @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1708-1717 | 1708-1717 | T125 | Treatment | TREATS | 1,708 | 1,717 | preserve | 1783-1800 | 1791-1800 | T122 | hormone analogues | Hormone | 1,783 | 1,800 | preserve | 1721-1725 | 1721-1725 | T119 | dogs | Mammal | 1,721 | 1,725 | A6 | Treatment of dogs with heart failure with thyroid hormone or thyroid hormone analogues may improve cardiac performance. | 1708-1839 | 1,708 | 1,839 | @PREDICAT$ of @OBJECT$ with heart failure with thyroid hormone or thyroid @SUBJECT$ may improve cardiac performance. |
Fact | preserve | 413-415 | 413-415 | T40 | in | LOCATION_OF | 413 | 415 | preserve | 420-430 | 420-430 | T32 | myocardium | Tissue | 420 | 430 | preserve | 371-381 | 374-379 | T29 | TR alpha 2 | OrganicChemical | 371 | 381 | A8 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and dogs with heart failure caused by dilated cardiomyopathy (DCM; 7) or chronic valvular disease (CVD; 7). | 342-601 | 342 | 601 | PROCEDURE: Concentrations of @OBJECT$ , beta 1, and beta 2 mRNA @PREDICAT$ the @SUBJECT$ were determined for clinically normal dogs (n = 7) and dogs with heart failure caused by dilated cardiomyopathy (DCM; 7) or chronic valvular disease (CVD; 7). |
Fact | preserve | 105-109 | 105-109 | T12 | with | PROCESS_OF | 105 | 109 | preserve | 136-160 | 153-160 | T9 | chronic valvular disease | DiseaseOrSyndrome | 136 | 160 | preserve | 100-104 | 100-104 | T6 | dogs | Mammal | 100 | 104 | A10 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the myocardium of dogs with dilated cardiomyopathy or chronic valvular disease. | 0-161 | 0 | 161 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the myocardium of @OBJECT$ @PREDICAT$ dilated cardiomyopathy or @SUBJECT$ . |
Fact | preserve | 296-298 | 296-298 | T22 | of | PART_OF | 296 | 298 | preserve | 285-295 | 285-295 | T18 | myocardium | Tissue | 285 | 295 | preserve | 299-303 | 299-303 | T19 | dogs | Mammal | 299 | 303 | A12 | OBJECTIVE: To investigate whether expression of thyroid hormone receptor (TR) messenger RNA (mRNA) is changed in the myocardium of dogs with heart failure. | 162-323 | 162 | 323 | OBJECTIVE: To investigate whether expression of thyroid hormone receptor (TR) messenger RNA (mRNA) is changed in the @SUBJECT$ @PREDICAT$ @OBJECT$ with heart failure. |
Fact | preserve | 97-99 | 97-99 | T11 | of | PART_OF | 97 | 99 | preserve | 86-96 | 86-96 | T5 | myocardium | Tissue | 86 | 96 | preserve | 100-104 | 100-104 | T6 | dogs | Mammal | 100 | 104 | A14 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the myocardium of dogs with dilated cardiomyopathy or chronic valvular disease. | 0-161 | 0 | 161 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the @SUBJECT$ @PREDICAT$ @OBJECT$ with dilated cardiomyopathy or chronic valvular disease. |
Fact | preserve | 1708-1717 | 1708-1717 | T125 | Treatment | TREATS | 1,708 | 1,717 | preserve | 1756-1771 | 1764-1771 | T121 | thyroid hormone | AminoAcidPeptideOrProtein | 1,756 | 1,771 | preserve | 1721-1725 | 1721-1725 | T119 | dogs | Mammal | 1,721 | 1,725 | A15 | Treatment of dogs with heart failure with thyroid hormone or thyroid hormone analogues may improve cardiac performance. | 1708-1839 | 1,708 | 1,839 | @PREDICAT$ of @OBJECT$ with heart failure with @SUBJECT$ or thyroid hormone analogues may improve cardiac performance. |
Fact | preserve | 516-522 | 516-522 | T43 | caused | CAUSES | 516 | 522 | preserve | 526-548 | 534-548 | T37 | dilated cardiomyopathy | DiseaseOrSyndrome | 526 | 548 | preserve | 502-515 | 508-515 | T36 | heart failure | DiseaseOrSyndrome | 502 | 515 | A17 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and dogs with heart failure caused by dilated cardiomyopathy (DCM; 7) or chronic valvular disease (CVD; 7). | 342-601 | 342 | 601 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and dogs with @OBJECT$ @PREDICAT$ by @SUBJECT$ (DCM; 7) or chronic valvular disease (CVD; 7). |
Fact | preserve | 575-591 | 584-591 | T45 | valvular disease | LOCATION_OF | 575 | 591 | preserve | 575-583 | 575-583 | T38 | valvular | BodyPartOrganOrOrganComponent | 575 | 583 | preserve | 561-591 | 584-591 | T39 | chronic valvular disease | DiseaseOrSyndrome | 561 | 591 | A18 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and dogs with heart failure caused by dilated cardiomyopathy (DCM; 7) or chronic valvular disease (CVD; 7). | 342-601 | 342 | 601 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and dogs with heart failure caused by dilated cardiomyopathy (DCM; 7) or @OBJECT$ @SUBJECT$ @PREDICAT$ (CVD; 7). |
Fact | preserve | 73-75 | 73-75 | T10 | in | LOCATION_OF | 73 | 75 | preserve | 86-96 | 86-96 | T5 | myocardium | Tissue | 86 | 96 | preserve | 16-47 | 41-45 | T2 | thyroid hormone receptor beta 1 | AminoAcidPeptideOrProtein | 16 | 47 | A19 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the myocardium of dogs with dilated cardiomyopathy or chronic valvular disease. | 0-161 | 0 | 161 | Upregulation of @OBJECT$ and beta 2 messenger RNA @PREDICAT$ the @SUBJECT$ of dogs with dilated cardiomyopathy or chronic valvular disease. |
Fact | preserve | 1708-1717 | 1708-1717 | T125 | Treatment | TREATS | 1,708 | 1,717 | preserve | 1783-1800 | 1791-1800 | T122 | hormone analogues | Hormone | 1,783 | 1,800 | preserve | 1731-1744 | 1737-1744 | T120 | heart failure | DiseaseOrSyndrome | 1,731 | 1,744 | A20 | Treatment of dogs with heart failure with thyroid hormone or thyroid hormone analogues may improve cardiac performance. | 1708-1839 | 1,708 | 1,839 | @PREDICAT$ of dogs with @OBJECT$ with thyroid hormone or thyroid @SUBJECT$ may improve cardiac performance. |
Fact | preserve | 105-109 | 105-109 | T12 | with | PROCESS_OF | 105 | 109 | preserve | 110-132 | 118-132 | T7 | dilated cardiomyopathy | DiseaseOrSyndrome | 110 | 132 | preserve | 100-104 | 100-104 | T6 | dogs | Mammal | 100 | 104 | A21 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the myocardium of dogs with dilated cardiomyopathy or chronic valvular disease. | 0-161 | 0 | 161 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the myocardium of @OBJECT$ @PREDICAT$ @SUBJECT$ or chronic valvular disease. |
Fact | preserve | 1726-1730 | 1726-1730 | T127 | with | PROCESS_OF | 1,726 | 1,730 | preserve | 1731-1744 | 1737-1744 | T120 | heart failure | DiseaseOrSyndrome | 1,731 | 1,744 | preserve | 1721-1725 | 1721-1725 | T119 | dogs | Mammal | 1,721 | 1,725 | A22 | Treatment of dogs with heart failure with thyroid hormone or thyroid hormone analogues may improve cardiac performance. | 1708-1839 | 1,708 | 1,839 | Treatment of @OBJECT$ @PREDICAT$ @SUBJECT$ with thyroid hormone or thyroid hormone analogues may improve cardiac performance. |
Fact | preserve | 1708-1717 | 1708-1717 | T125 | Treatment | TREATS | 1,708 | 1,717 | preserve | 1756-1771 | 1764-1771 | T121 | thyroid hormone | AminoAcidPeptideOrProtein | 1,756 | 1,771 | preserve | 1731-1744 | 1737-1744 | T120 | heart failure | DiseaseOrSyndrome | 1,731 | 1,744 | A23 | Treatment of dogs with heart failure with thyroid hormone or thyroid hormone analogues may improve cardiac performance. | 1708-1839 | 1,708 | 1,839 | @PREDICAT$ of dogs with @OBJECT$ with @SUBJECT$ or thyroid hormone analogues may improve cardiac performance. |
Fact | preserve | 497-501 | 497-501 | T41 | with | PROCESS_OF | 497 | 501 | preserve | 502-515 | 508-515 | T36 | heart failure | DiseaseOrSyndrome | 502 | 515 | preserve | 492-496 | 492-496 | T35 | dogs | Mammal | 492 | 496 | A24 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and dogs with heart failure caused by dilated cardiomyopathy (DCM; 7) or chronic valvular disease (CVD; 7). | 342-601 | 342 | 601 | PROCEDURE: Concentrations of TR alpha 2, beta 1, and beta 2 mRNA in the myocardium were determined for clinically normal dogs (n = 7) and @OBJECT$ @PREDICAT$ @SUBJECT$ caused by dilated cardiomyopathy (DCM; 7) or chronic valvular disease (CVD; 7). |
Fact | preserve | 144-160 | 153-160 | T14 | valvular disease | LOCATION_OF | 144 | 160 | preserve | 144-152 | 144-152 | T8 | valvular | BodyPartOrganOrOrganComponent | 144 | 152 | preserve | 136-160 | 153-160 | T9 | chronic valvular disease | DiseaseOrSyndrome | 136 | 160 | A25 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the myocardium of dogs with dilated cardiomyopathy or chronic valvular disease. | 0-161 | 0 | 161 | Upregulation of thyroid hormone receptor beta 1 and beta 2 messenger RNA in the myocardium of dogs with dilated cardiomyopathy or @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 1164-1166 | 1164-1166 | T86 | of | PART_OF | 1,164 | 1,166 | preserve | 1153-1163 | 1153-1163 | T79 | myocardium | Tissue | 1,153 | 1,163 | preserve | 1167-1171 | 1167-1171 | T80 | dogs | Mammal | 1,167 | 1,171 | A26 | Thyroid hormone receptor beta 1 mRNA was upregulated approximately threefold, and TR beta 2 mRNA was upregulated approximately eightfold in myocardium of dogs with DCM and CVD, compared with clinically normal dogs. | 1001-1233 | 1,001 | 1,233 | Thyroid hormone receptor beta 1 mRNA was upregulated approximately threefold, and TR beta 2 mRNA was upregulated approximately eightfold in @SUBJECT$ @PREDICAT$ @OBJECT$ with DCM and CVD, compared with clinically normal dogs. |
Fact | preserve | 61-103 | 91-103 | T12 | Carvedilol is a non-selective beta-blocker | ISA | 61 | 103 | preserve | 61-71 | 61-71 | T6 | Carvedilol | OrganicChemical | 61 | 71 | preserve | 91-103 | 91-103 | T7 | beta-blocker | PharmacologicSubstance | 91 | 103 | A2 | Carvedilol is a non-selective beta-blocker, and the only one, in recent clinical trials, to have shown a clear reduction in mortality. | 61-202 | 61 | 202 | @SUBJECT$ @PREDICAT$ @OBJECT$ , and the only one, in recent clinical trials, to have shown a clear reduction in mortality. |